Literature DB >> 29922006

Sonidegib for basal cell carcinoma.

.   

Abstract

Entities:  

Year:  2018        PMID： 29922006      PMCID： PMC6003011          DOI： 10.18773/austprescr.2018.025

Source DB:  PubMed          Journal:  Aust Prescr        ISSN： 0312-8008


× No keyword cloud information.
  2 in total

1.  Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial.

Authors:  Michael R Migden; Alexander Guminski; Ralf Gutzmer; Luc Dirix; Karl D Lewis; Patrick Combemale; Robert M Herd; Ragini Kudchadkar; Uwe Trefzer; Sven Gogov; Celine Pallaud; Tingting Yi; Manisha Mone; Martin Kaatz; Carmen Loquai; Alexander J Stratigos; Hans-Joachim Schulze; Ruth Plummer; Anne Lynn S Chang; Frank Cornélis; John T Lear; Dalila Sellami; Reinhard Dummer
Journal:  Lancet Oncol       Date:  2015-05-14       Impact factor: 41.316

2.  Long-term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30-month analysis of the randomized phase 2 BOLT study.

Authors:  J T Lear; M R Migden; K D Lewis; A L S Chang; A Guminski; R Gutzmer; L Dirix; P Combemale; A Stratigos; R Plummer; H Castro; T Yi; M Mone; J Zhou; U Trefzer; M Kaatz; C Loquai; R Kudchadkar; D Sellami; R Dummer
Journal:  J Eur Acad Dermatol Venereol       Date:  2017-11-06       Impact factor: 6.166
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.